Get the Stockscreener App
2.12
1.44%
0.03
After Hours:
2.06
-0.06
-2.83%
Veraxa Biotech Ag stock is traded at $2.12, with a volume of 179.12K.
It is up +1.44% in the last 24 hours and down -90.03% over the past month.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
See More
Previous Close:
$2.09
Open:
$2.08
24h Volume:
179.12K
Relative Volume:
0.52
Market Cap:
$299.78M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-23.19%
1M Performance:
-90.03%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.04
$2.1886
1-Week Range:
$2.00
$2.917
52-Week Range:
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Compare VRXA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
2.12 | 302.61M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
477.08 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.45 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.93 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.44 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.14 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Veraxa Biotech Ag Stock (VRXA) Latest News
VERAXA Biotech Leverages AI Partnership to Advance Cancer Therapy Platform - citybuzz -
VERAXA Biotech Appoints Carl von Halem as Interim CFO Amid Permanent Candidate Search - citybuzz -
VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development - NewMediaWire
VERAXA Biotech Partners with Ardigen to Integrate AI in Cancer Drug Development - citybuzz -
Veraxa partners with Ardigen on AI-driven cancer target selection - Investing.com UK
AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline - EIN Presswire
Veraxa Uses AI to Advance BiTAC Pipeline - AllSci
VERAXA Biotech AG Announces AI Collaboration with Ardigen to Support BiTAC Cancer Therapeutics Pipeline - Quiver Quantitative
AI partnership aims to sharpen cancer target selection at VERAXA - Stock Titan
VERAXA Biotech names Carl von Halem as interim CFO - Investing.com
VERAXA Biotech names Carl von Halem interim CFO as it seeks permanent successor. - Pluang
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister - The Manila Times
Veraxa Biotech AG Announces CFO Changes - marketscreener.com
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to ... - Caledonian Record
VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Pa - Benzinga
VERAXA Biotech Advances Lead Cancer Drug Candidate with ATUM Cell Line Development Partnership - citybuzz -
Diluted earnings per share (diluted EPS) of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Veraxa Biotech AG Company Profile & Introduction - Moomoo
VERAXA Biotech (VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - NewMediaWire
Non-controlling/minority interest of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Benzinga
VRXA Price History for Veraxa Biotech Ag Stock - Barchart.com
VRXA | Veraxa Biotech AG Ordinary Institutional Ownership - Quiver Quantitative
VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News - Quiver Quantitative
VERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - NewMediaWire
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026 - citybuzz -
VERAXA Biotech Advances BiTAC Pipeline, Seeks Pharma Partnerships to Fund Cancer Therapies - citybuzz -
VERAXA Biotech targets 2028 IND filing for lead candidate - Investing.com UK
VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com - Investing.com South Africa
VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - TradingView
The Cancer Therapy Strategy VERAXA Is Betting the Company On - Yahoo Finance
VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships. - Pluang
VERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategy - Quiver Quantitative
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - The Manila Times
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and ... - Caledonian Record
VERAXA says its BiTAC cancer pipeline is drawing partner interest - Stock Titan
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Yahoo Finance
VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - NewMediaWire
VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - USA Today
VERAXA Biotech Begins Cell Line Development for BiTAC Cancer Therapy, Aiming to Improve Tumor Selectivity - citybuzz -
Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan
Veraxa initiates cell line development for lead cancer therapy By Investing.com - Investing.com Nigeria
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program - The Manila Times
VERAXA advances lead cancer drug toward manufacturing work with ATUM - Stock Titan
Antibody Therapeutics Deals Signal Value Creation for Early-Stage Biotechs Like VERAXA - MEXC
Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals - NewMediaWire
Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sect - Benzinga
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to sales forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Veraxa Biotech Ag Stock (VRXA) Financials Data
There is no financial data for Veraxa Biotech Ag (VRXA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.27%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):